(AFP/JUSTIN TALLIS)
The Franco-Austrian pharmaceutical group Valneva is counting on an increase in its sales for 2024, notably with the marketing of its vaccine against chikungunya, Ixchiq, approved in the United States last November, it said on Thursday.
“Product sales are expected between 150 and 180 million euros in 2024, subject to the availability of Ixiaro (against a form of mosquito-borne encephalitis: editor’s note) and third-party products, as well as the performance of Ixchiq sales during the first year of the vaccine’s launch in the United States,” he detailed in a press release.
2024 sales should reflect “continued growth in sales of existing products (Ixiaro, Dukoral – against cholera), a decline in sales of third-party products linked to supply problems and the first sales” of Ixchiq.
“Our goal in 2024 is to continue to take advantage of the recovery of the travel industry to continue the commercial growth of our existing products and to record the first sales” of Ixchiq, said Peter Bruehler, CFO of the specialist group in vaccines, cited in the press release.
For 2023, Valneva recorded revenue of 153.7 million euros, compared to 361.3 in 2022 — this amount included 280 million euros of revenue related to Covid-19 vaccine supply agreements , announced the group.
Product sales alone totaled 144.6 million euros in 2023, compared to 114.8 million in 2022.
Valneva received the green light from the United States in November 2023 to launch its single-dose chikungunya vaccine – the first to be marketed – for people aged 18 and over and at increased risk of exposure. to the virus.
A few days later, the European Medicines Agency (EMA) deemed the application for marketing authorization for this same vaccine admissible.
On the Paris Stock Exchange, the stock fell 3.16% to 3.64 euros at the start of the morning, in a market up 0.89%.